Media Summary: Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses measurable residual ... Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease ( Benjamin Derman, MD, University of Chicago, Chicago, IL, shares insights into the use of measurable residual disease (
Mrd Guided Therapy For Myeloma - Detailed Analysis & Overview
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses measurable residual ... Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease ( Benjamin Derman, MD, University of Chicago, Chicago, IL, shares insights into the use of measurable residual disease ( Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the updated results of the MIDAS study ... Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, talks on the use of measurable residual disease ( Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, comments on the role of measurable residual disease ...
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, comments on the use of ... Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, talks ... Mattia D'Agostino, MD, University of Turin, European Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the potential for ... Luca Bertamini, MD, Erasmus MC, Rotterdam, Netherlands, discusses the future of In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the pros and cons of using ...
Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, comments on the evolving use of measurable residual ... Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, talks on the use of ... Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the use of measurable residual disease ( Benjamin Derman, MD, from the University of Chicago, Chicago, IL, talks about how Discover how measurable residual disease ( Nikhil C. Munshi, MD, and Parameswaran Hari, MD, MRCP, debate the role of minimal residual disease (
Sagar Lonial, MD, FCAP, from the Winship Cancer Institute, Atlanta, GA, talks about why minimal residual disease (
